{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-029514","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2026-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.485571+00:00","generated_at":"2026-05-16T06:16:14.694143+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lexicon launches public offering, private placement; reports $125.2M cash, Novo milestone, clinical timelines","bullets":["Underwritten public offering of common stock launched; Jefferies and Piper Sandler joint book-running managers.","Concurrent private placement to Invus affiliate via preemptive right; option to purchase additional shares pro rata.","Preliminary cash position $125.2M (unaudited) as of year-end 2025; $10M milestone received from Novo Nordisk in Jan 2026.","SONATA-HCM (sotagliflozin) Phase 3 enrollment completion expected mid-2026; topline data Q1 2027.","NDA resubmission for ZYNQUISTA in type 1 diabetes potentially in 2026, supported by STENO1 safety data."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-029514","json":"https://secwatch.observer/filing/0001193125-26-029514.json","markdown":"https://secwatch.observer/filing/0001193125-26-029514.md","text":"https://secwatch.observer/filing/0001193125-26-029514.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000119312526029514/0001193125-26-029514-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000119312526029514/d61153d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T06:16:14.694143+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}